First hemophilia B patients in Denmark treated with Hemgenix
For the first time in Denmark, people with hemophilia B have been treated with the gene therapy Hemgenix…
Articles by Marisa Wexler, MS
Metagenomi aiming for clinical trials of gene-editing therapy in 2026
Metagenomi is now working on preclinical studies to advance MGX-001, its experimental gene-editing therapy for hemophilia A, with…
Clotting factor proteins may affect bone cell activity, study finds
Clotting proteins that are missing or are defective in hemophilia can directly affect the activity of cells responsible for…
Committee recommends approval in EU of concizumab for hemophilia
A European Medicines Agency (EMA) committee has recommended the approval of Novo Nordisk’s concizumab as a prophylactic, or preventive,…
Altuviiio prevents bleeds in young children with severe hem A: Trial
Nearly two-thirds of children with severe hemophilia A on preventive, or prophylactic, treatment with once-weekly Altuviiio (efanesoctocog alfa) in…
Fitusiran reviewed for hemophilia A, B, with or without inhibitors
Note: This article was updated June 26, 2024, to clarify that the analysis of fitusiran in surgery was conducted in…
Most GENEr8-1 trial patients bleed-free 4 years after Roctavian
More than half the adults with hemophilia A in the Phase 3 GENEr8-1 clinical trial remain completely free of…
‘Equitable access for all’ is theme of today’s World Hemophilia Day
World Hemophilia Day is today, April 17, and this year’s chosen theme by the World Federation for Hemophilia…
TiumBio plans Phase 1b TU7710 trial in hemophilia with inhibitors
TiumBio is preparing to launch a Phase 1b clinical trial to test TU7710, its experimental treatment to manage bleeding…
Risk of severe hemorrhage after childbirth ‘alarmingly high’: Study
Women with hemophilia and other bleeding disorders are more likely to experience postpartum hemorrhage and other bleeding problems related…